Hao et al. showed that APOC1 + macrophage was abundant in HCC tissues, and APOC1 inhibitor could reshape M2 macrophage to M1 phenotype and enhance the anti-PD-1 immunotherapy [21]. Here, APOC1 is linked to hepatocellular carcinoma.